Advertisement

Stable Angina

  • Sachin Mehta
  • Neal Kleiman
Chapter

Abstract

In the USA, it is estimated that there are more than 13 million people with coronary artery disease (CAD). Beyond a thorough history and physical, there are several diagnostic tests used to detect CAD. If indicated, medications with different mechanistic behaviors are used to prevent cardiac injury and provide symptomatic relief. In addition to medical therapy, revascularization plays a significant function in treatment. The roles of coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) have evolved over the past several decades. The decision to pursue revascularization and the type of procedure to perform depends on the amount of ischemic burden. Additionally, if a patient continues to have symptoms despite optimal medical therapy, revascularization should be considered. Finally, exercise is a key component in treating CAD. Every patient should be instructed to perform exercise training to supplement medical therapy and revascularization procedures for optimal treatment.

Keywords

Percutaneous Coronary Intervention Coronary Artery Bypass Grafting Stable Angina Stent Thrombosis Cardiac Rehabilitation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Thom T et al. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–151.PubMedGoogle Scholar
  2. 2.
    Georgeson S et al. Acute cardiac ischemia in patients with syncope: importance of the initial electrocardiogram. J Gen Intern Med. 1992;7(4):379–86.PubMedGoogle Scholar
  3. 3.
    Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMedGoogle Scholar
  4. 4.
    Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–44.PubMedGoogle Scholar
  5. 5.
    Folsom AR, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002;144:233–8.PubMedGoogle Scholar
  6. 6.
    Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.PubMedGoogle Scholar
  7. 7.
    Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–81.PubMedGoogle Scholar
  8. 8.
    Leonard DA, Merhige ME, Williams BA, et al. Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease. Coron Artery Dis. 2011;22(7):491–6.PubMedGoogle Scholar
  9. 9.
    Schunkert H, König IR, Kathiresan S. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333–8.PubMedGoogle Scholar
  10. 10.
    Wang Y, Zheng Y, Zheng W, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50(8):760–7.PubMedGoogle Scholar
  11. 11.
    Shiffman D, Rowland CM, Sninsky JJ, et al. Polymorphisms associated with coronary heart disease: better by the score. Curr Opin Mol Ther. 2006;8(6):493–9.PubMedGoogle Scholar
  12. 12.
    Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44(7):1429–35.PubMedGoogle Scholar
  13. 13.
    Ohashi K, Ouchi N, Kihara S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43(7):1195–200.PubMedGoogle Scholar
  14. 14.
    Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004;110(15):2132–6.PubMedGoogle Scholar
  15. 15.
    Roberts R, Stewart AF. 9p21 and the genetic revolution for coronary artery disease. Clin Chem. 2012;58(1):104–12.PubMedGoogle Scholar
  16. 16.
    International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103–9.Google Scholar
  17. 17.
    Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation. 1989;80:87–98.PubMedGoogle Scholar
  18. 18.
    Campeau L. Grading of angina pectoris. Circulation. 1976;54:522–3.PubMedGoogle Scholar
  19. 19.
    Bourque JM, Charlton GT, Holland BH, et al. Prognosis in patients achieving ≥10 METS on exercise stress testing: was SPECT imaging useful? J Nucl Cardiol. 2011;18(2):230–7.PubMedGoogle Scholar
  20. 20.
    Kaul S, Boucher CA, Newell JB, et al. Determination of the quantitative thallium imaging variables that optimize detection of coronary artery disease. J Am Coll Cardiol. 1986;7:527.PubMedGoogle Scholar
  21. 21.
    Husain Z, Palani G, Cabrera R, et al. Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging. 2011;28(7):1841–9.PubMedGoogle Scholar
  22. 22.
    Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54(13):1123–30.PubMedGoogle Scholar
  23. 23.
    Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol. 2012;19(1):126–41.PubMedGoogle Scholar
  24. 24.
    Gibbons RJ, Fyke FE, Clements IP, et al. Noninvasive identification of severe coronary artery disease using exercise radionuclide angiography. J Am Coll Cardiol. 1988;11:28.PubMedGoogle Scholar
  25. 25.
    Quinones MA, Verani MS, Haichin RM, et al. Exercise echocardiography versus T1-201 single photon emission computerized tomography in evaluation of coronary artery disease: analysis of 292 patients. Circulation. 1992;85:1026–31.PubMedGoogle Scholar
  26. 26.
    FAA. Coronary artery disease. 2012. http://www.faa.gov/licenses_certificates/medical_certification/specialissuance/coronary. Last accessed 10 May 2012.
  27. 27.
    International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Clinical trials. 2012. http://clinicaltrials.gov/ct2/show/NCT01471522. Last accessed 10 May 2012.
  28. 28.
    Maron DJ, Stone GW, Berman DS, et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. Am Heart J. 2011;162(6):1034–43.PubMedGoogle Scholar
  29. 29.
    Galbraith JE, Murphy ML, Desoyza N. Coronary angiogram interpretation: interobserver variability. JAMA. 1981;240:2053–9.Google Scholar
  30. 30.
    Grodin CM, Dydra I, Pastgernac A, et al. Discrepancies between cineangiographic and post-mortem findings in patients with coronary artery disease and recent myocardial revascularization. Circulation. 1974;49:703–9.Google Scholar
  31. 31.
    Lowe HC, Narula J, Fujimoto JG, et al. Intracoronary optical diagnostics current status, limitations, and potential. JACC Cardiovasc Interv. 2011;4(12):1257–70.PubMedGoogle Scholar
  32. 32.
    Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenosis. N Engl J Med. 1996;34:1703–8.Google Scholar
  33. 33.
    Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995;92(11):3183–93.PubMedGoogle Scholar
  34. 34.
    Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.PubMedGoogle Scholar
  35. 35.
    Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177–84.PubMedGoogle Scholar
  36. 36.
    Iskandrian AS, Chae SC, Heo J, et al. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. J Am Coll Cardiol. 1993;22:665–70.PubMedGoogle Scholar
  37. 37.
    Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death. Circulation. 1998;97:535–43.PubMedGoogle Scholar
  38. 38.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged anti platelet therapy in various categories of patients. Br Med J. 1994;308:81–98.Google Scholar
  39. 39.
    Topol EJ, Easton D, Harrington RA, BRAVO Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406.PubMedGoogle Scholar
  40. 40.
    Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5.PubMedGoogle Scholar
  41. 41.
    Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.PubMedGoogle Scholar
  42. 42.
    Conley PB, Delaney SM. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in throm- bosis. Curr Opin Hematol. 2003;10:333–8.PubMedGoogle Scholar
  43. 43.
    Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–5.PubMedGoogle Scholar
  44. 44.
    Cannon CP, CAPRIE Investigators. Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Am J Cardiol. 2002;90:760–2.PubMedGoogle Scholar
  45. 45.
    Steinhubl SR, Berger PB, Mann III JT, et al. Clopidogrel for the reduction of events during observation. JAMA. 2002;288:2411–20.PubMedGoogle Scholar
  46. 46.
    CURE Trial Investigators. Clopidogrel in unstable angina to prevent recurrent events. N Engl J Med. 2001;345:494–502.Google Scholar
  47. 47.
    Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.PubMedGoogle Scholar
  48. 48.
    Abrams J. Third North American conference on nitroglycerine therapy. Am J Cardiol. 1992;70:1B–103.Google Scholar
  49. 49.
    Cheitlin MD, Hutter Jr AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: ACC/AHA expert consensus document. Circulation. 1999;99:168–77.PubMedGoogle Scholar
  50. 50.
    Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855–60.PubMedGoogle Scholar
  51. 51.
    The BHAT Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. The beta-blocker heart attack trial. JAMA. 1982;247:1707–14.Google Scholar
  52. 52.
    The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J. 1985;6:199–211.Google Scholar
  53. 53.
    The ISIS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;ii:57–66.Google Scholar
  54. 54.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–14.PubMedGoogle Scholar
  55. 55.
    Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–45.PubMedGoogle Scholar
  56. 56.
    Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:1949–54.PubMedGoogle Scholar
  57. 57.
    The MDPIT Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–92.Google Scholar
  58. 58.
    The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol. 1990;66:779–85.Google Scholar
  59. 59.
    Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462.PubMedGoogle Scholar
  60. 60.
    Chaitman BR, Pepine CJ, Parker J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309.PubMedGoogle Scholar
  61. 61.
    Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566.PubMedGoogle Scholar
  62. 62.
    Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375.PubMedGoogle Scholar
  63. 63.
    The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–7.Google Scholar
  64. 64.
    The Air Force/Texas Coronary Atherosclerosis Prevention Research Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–22.Google Scholar
  65. 65.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
  66. 66.
    The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.Google Scholar
  67. 67.
    ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.Google Scholar
  68. 68.
    Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.Google Scholar
  69. 69.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT). N Engl J Med. 2004;350:1495–504.PubMedGoogle Scholar
  70. 70.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227–39.PubMedGoogle Scholar
  71. 71.
    Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation. 1998;97:1029–36.PubMedGoogle Scholar
  72. 72.
    Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93:307–12.PubMedGoogle Scholar
  73. 73.
    McKenney JM, McCormick LS, Weiss S, et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104:137–43.PubMedGoogle Scholar
  74. 74.
    Investigators WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women—principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.Google Scholar
  75. 75.
    The Heart and Estrogen/progestin Replacement Study (HERS) Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–13.Google Scholar
  76. 76.
    The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199–208.Google Scholar
  77. 77.
    Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062–71.PubMedGoogle Scholar
  78. 78.
    Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.PubMedGoogle Scholar
  79. 79.
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991;325:756.PubMedGoogle Scholar
  80. 80.
    Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.PubMedGoogle Scholar
  81. 81.
    Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha-tocopherol and beta-carotene supplements on symptoms, progression, and prognosis in angina pectoris. Heart. 1998;79:454–8.PubMedGoogle Scholar
  82. 82.
    Stephens NG, Parsons A, Schofiled PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.PubMedGoogle Scholar
  83. 83.
    GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet. 1999;354:447–55.Google Scholar
  84. 84.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145–53.Google Scholar
  85. 85.
    Barnard RJ, MacAlpin R, Kattus AA, et al. Effect on training on myocardial oxygen supply/demand balance. Circulation. 1977;56(2):289.PubMedGoogle Scholar
  86. 86.
    Dressendorfer RH, Smith JL, Amsterdam EA, et al. Reduction of submaximal exercise myocardial oxygen demand post-walk training program in coronary patients due to improved physical work efficiency. Am Heart J. 1982;103(3):358.PubMedGoogle Scholar
  87. 87.
    Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109(11):1371.PubMedGoogle Scholar
  88. 88.
    Walther C, Möbius-Winkler S, Linke A, et al. Regular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2008;15(1):107–12.PubMedGoogle Scholar
  89. 89.
    Onishi T, Shimada K, Sato H, et al. Effects of phase III cardiac rehabilitation on mortality and cardiovascular events in elderly patients with stable coronary artery disease. Circ J. 2010;74(4):709–14.PubMedGoogle Scholar
  90. 90.
    Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682.PubMedGoogle Scholar
  91. 91.
    Soga Y, Yokoi H, Amemiya K, et al. Safety and efficacy of exercise training after coronary stenting in patients with stable coronary artery disease. Circ J. 2011;75(10):2379–86.PubMedGoogle Scholar
  92. 92.
    Yoshikawa D, Ishii H, Kurebayashi N, et al. Association of cardiorespiratory fitness with characteristics of coronary plaque: assessment using integrated backscatter intravascular ultrasound and optical coherence tomography. Int J Cardiol. 2011;162(2):123–8.PubMedGoogle Scholar
  93. 93.
    Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.PubMedGoogle Scholar
  94. 94.
    Fernández-Ortiz J, Badimon J, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562–9.PubMedGoogle Scholar
  95. 95.
    Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation. 1964;30:654–70.PubMedGoogle Scholar
  96. 96.
    King III SB. Angioplasty from bench to bedside to bench. Circulation. 1996;93:1621–9.PubMedGoogle Scholar
  97. 97.
    Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58(1):19–25.PubMedGoogle Scholar
  98. 98.
    The EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–96.Google Scholar
  99. 99.
    The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92.Google Scholar
  100. 100.
    The SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coro- nary artery. N Engl J Med. 2003;349:1315–23.Google Scholar
  101. 101.
    Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate- release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–94.PubMedGoogle Scholar
  102. 102.
    RAVEL Study Group. Randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.Google Scholar
  103. 103.
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527.PubMedGoogle Scholar
  104. 104.
    Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.PubMedGoogle Scholar
  105. 105.
    McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–21.PubMedGoogle Scholar
  106. 106.
    Kuntz RE, Baim DS. Defining coronary restenosis. Circulation. 1993;88:1310.PubMedGoogle Scholar
  107. 107.
    Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J. 2000;21(21):1739.PubMedGoogle Scholar
  108. 108.
    Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30(6):1428.PubMedGoogle Scholar
  109. 109.
    Goldberg SL, Loussararian A, De Gregorio J, et al. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol. 2001;37(4):1019.PubMedGoogle Scholar
  110. 110.
    Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT I). Circulation. 1995;91:2158.PubMedGoogle Scholar
  111. 111.
    Baim DS, Cutlip DE, Sharma SK, et al. Final results of the balloon versus optimal atherectomy trial. Circulation. 1998;97:322–31.PubMedGoogle Scholar
  112. 112.
    Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997;96:91–8.PubMedGoogle Scholar
  113. 113.
    Semenza GL, Agani F, Iyer N, et al. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest. 1998;114:40S–5.PubMedGoogle Scholar
  114. 114.
    Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626–33.PubMedGoogle Scholar
  115. 115.
    Shyu KG, Wang MT, Wang BW, et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hy- brid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res. 2002;54:576–83.PubMedGoogle Scholar
  116. 116.
    Isner JM. Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Am J Cardiol. 1998;10A:63S–4.Google Scholar
  117. 117.
    Goncalves LM. Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev Port Cardiol. 1998;17(2s):II11–20.PubMedGoogle Scholar
  118. 118.
    Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114–23.PubMedGoogle Scholar
  119. 119.
    Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation. 1998;97:645–50.PubMedGoogle Scholar
  120. 120.
    Grines CL, Watkins MW, Mahmarian JJ, AngiogeneGENe Therapy (AGENT-2) Study Group, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42(8):1339.PubMedGoogle Scholar
  121. 121.
    Van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009;301(19):1997.PubMedGoogle Scholar
  122. 122.
    Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361(9351):47.PubMedGoogle Scholar
  123. 123.
    Fuchs S, Satler LF, Kornowsk R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol. 2003;41(10):1721.PubMedGoogle Scholar
  124. 124.
    Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004;110(11 Suppl 1):II213.PubMedGoogle Scholar
  125. 125.
    Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107(18):2294.PubMedGoogle Scholar
  126. 126.
    Garrett HE, Dennis EW, DeBakey ME, et al. Aortocoronary bypass with saphenous vein graft: seven-year follow-up. JAMA. 1973;223:792–4.PubMedGoogle Scholar
  127. 127.
    Favaloro RG. Bilateral internal mammary artery implants: operative technique: a preliminary report. Cleve Clin Q. 1967;34:61–6.PubMedGoogle Scholar
  128. 128.
    Favaloro RG. Landmarks in the development of coronary artery bypass surgery. Circulation. 1998;98:466–78.PubMedGoogle Scholar
  129. 129.
    Cameron AAC, Davis KB, Rogers WJ, et al. Recurrence of angina after coronary bypass surgery. Predictors and prognosis (CASS registry). J Am Coll Cardiol. 1995;26:895–9.PubMedGoogle Scholar
  130. 130.
    Borger MA, Cohen G, Buth KJ, et al. Multiple arterial grafts. Radial versus right internal thoracic arteries. Circulation. 1998;98:II-7–14.Google Scholar
  131. 131.
    Fletcher GF, Balady G, Froelicher VF, et al. Exercise standards: a statement for health professionals from the American Heart Association Writing Group. Circulation. 1995;91:580–615.PubMedGoogle Scholar
  132. 132.
    Parisi AF, Folland ED, Hartigan P. Angioplasty compared to medicine. N Engl J Med. 1992;326:10–6.PubMedGoogle Scholar
  133. 133.
    RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomized Intervention Treatment of Angina (RITA-2) trial. Lancet. 1997;350:461–8.Google Scholar
  134. 134.
    Yusuf S, Zucker D, Pedruzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10- year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–70.PubMedGoogle Scholar
  135. 135.
    BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.Google Scholar
  136. 136.
    Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503.PubMedGoogle Scholar
  137. 137.
    Shaw L, Berman D, Maron D, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.PubMedGoogle Scholar
  138. 138.
    The BARI (Bypass Angioplasty Revascularization Investigation) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multi-vessel disease. N Engl J Med. 1996;335:217–25.Google Scholar
  139. 139.
    Abizaid A, Costa MA, Centemero M, Arterial Revascularization Therapy Study Group, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104:553–8.Google Scholar
  140. 140.
    Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961.PubMedGoogle Scholar
  141. 141.
    Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219.PubMedGoogle Scholar
  142. 142.
    Morice MC, Serruys PW, Kappetein A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121(24):2645–53.PubMedGoogle Scholar
  143. 143.
    Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364(18):1718–27.PubMedGoogle Scholar

Recommended Reading

  1. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–25.PubMedGoogle Scholar
  2. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165–7.PubMedGoogle Scholar
  3. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203.PubMedGoogle Scholar
  4. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591–602.PubMedGoogle Scholar
  5. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920–59.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of CardiologyBaylor College of MedicineHoustonUSA
  2. 2.Cardiac Catheterization LaboratoriesThe Methodist Debakey Heart and Vascular CenterHoustonUSA
  3. 3.Department of MedicineWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations